

INTERNATIONAL  
JOURNAL  
*of*  
**SPINE**  
**SURGERY**

## ISASS Policy Statement – Cervical Artificial Disc

Domagoj Coric

*Int J Spine Surg* 2014, 8 ()

doi: <https://doi.org/10.14444/1006>

<https://www.ijssurgery.com/content/8/6>

This information is current as of May 17, 2025.

---

**Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at:  
<http://ijssurgery.com/alerts>

**INTERNATIONAL  
JOURNAL  
*of*  
SPINE  
SURGERY**

This article generously published free of charge by the International Society for the Advancement of Spine Surgery.



# ISASS Policy Statement – Cervical Artificial Disc

---

*Domagoj Coric, MD*

*Department of Neurosurgery, Carolinas Medical Center, Charlotte, NC USA*

---

## ***Introduction***

*Morgan Lorio, MD, FACS, Chair, ISASS Task Force on Coding & Reimbursement*

*The ISASS Task Force reached out to Domagoj Coric, MD to provide a timely summation on cervical disc arthroplasty given his special interest and recent IASP championship of this innovative technology to insure enhanced spine patient access. The ISASS Task Force is pleased with this step towards published ISASS societal policy and applauds Dr. Coric's effort; if ISASS is to continue to succeed we must continually harness the voluntary talents and energies of our members with gratitude.*

---

**keywords:** policy

*Volume 8 Article 6 doi: 10.14444/1006*

---

## ***Background***

Cervical total disc replacement (cTDR) was first introduced in Europe in the late 1990s.<sup>1, 2, 3, 4</sup> Subsequently, three prospective, randomized Food and Drug Administration (FDA) regulated Investigational Device Exemption (IDE) trials were initiated in the US dating back to 2000.<sup>5, 6, 7</sup> These initial IDE studies ultimately led to the first three FDA approvals for cTDR devices in the US, Prestige ST<sup>5</sup> (Medtronic- 541 patients, 32 sites) (2007), Prodisc-C<sup>6</sup> (Depuy Synthes- 209 patients, 13 sites) (2008) and Bryan Disc<sup>7</sup> (Medtronic- 463 patients, 30 sites) (2009), for the treatment of 1-level cervical spondylosis from C3-7. There have been an additional three FDA approvals, Secure-C<sup>8</sup> (Globus Medical- 380 patients, 18 sites), PCM<sup>9</sup> (Nuvasive- 342 patients, 24 sites) (2012) and Mobi-C<sup>10</sup> (LDR- 1level: 260 patients, 24 sites; 2 level: 339 patients) (2013). There has also been a new indication as Mobi-C was also approved for treatment of two-level cervical spondylosis C3-7.<sup>10</sup>

All the US FDA IDE trials compared cTDR devices to standard anterior discectomy and fusion (ACDF) in prospective and randomized studies producing Level 1 data. As with all industry-sponsored studies, bias, both investigator and patient related, is a concern. This concern was somewhat mitigated by the fact that these IDE studies have cumulatively involved over 2,500 patients at over 100 study sites (Table 1). Furthermore, these studies utilized similar validated outcome measures including Neck Disability Index (NDI), Visual Analog Scale (VAS) and SF-36. ACDF is an established surgical procedure with a

well-documented safety and efficacy dating back 60 years.<sup>11, 12, 13, 14</sup> Cervical arthroplasty offers some theoretical advantages over ACDF.<sup>15, 16, 17</sup> ACDF results in loss of motion at the index level(s), placing increased stress on adjacent levels above and below the fusion.<sup>18, 19, 20, 21, 22, 23, 24, 25, 26, 27</sup> There is a documented incidence of clinically symptomatic adjacent-level disc disease following ACDF ranging from 0.5-3% annually.<sup>13, 14, 28</sup> Hilibrand et al.<sup>20</sup> reported a rate of symptomatic adjacent-level degeneration following ACDF of 2.9% annually, although the rate of adjacent level re-operation was only 0.7% per year. Similarly, Robertson and associates reported a symptomatic adjacent-segment degenerative disc disease rate of 7% in the anterior fusion series. By preserving motion at the operated level, cTDR has the potential to positively affect the occurrence of adjacent segment degeneration.<sup>29, 30, 31, 32</sup>

Table 1. FDA-approved cTDR devices with number of patients enrolled in pivotal IDE study.

<i>cTDR Device</i>	<i># of Patients</i>
Prestige ST	541
Prodisc-C	209
Bryan Disc	463
Secure-C	380
PCM	342
Mobi-C 1-level	260
Mobi-C 2-level	339
<b>TOTAL</b>	<b>2534</b>

In order to establish an evidence based rationale for cTDR as a viable therapeutic modality in the treatment of cervical radiculopathy, cervical artificial discs must satisfy several criteria. They must show clinical efficacy and safety through the regulatory IDE process and receive the appropriate regulatory approval. Additionally, cervical arthroplasty must validate that the technique maintains segmental motion with concomitant decreased adjacent level stresses compared to ACDF. Furthermore, the results of multi-center controlled studies should be replicated at individual centers. Intermediate term data should reaffirm safety and efficacy beyond the two year follow-up mandated by FDA IDE process. Once accepted as reasonable treatment option, long-term data should be utilized to refine ideal indications for that procedure.<sup>33</sup>

## Results

The results of seven different prospective, randomized studies have been published in peer-reviewed literature.<sup>5, 6, 7, 8, 10, 34, 35</sup> These studies, comparing cTDR to standard anterior cervical discectomy and fusion (ACDF), have shown positive results for cTDR leading to six different FDA approvals. Although the statistical design of these studies was “non-inferiority.” on numerous clinical end-points, artificial discs were found to be statistically superior to fusion. Mummaneni and colleagues showed statistically significant higher neurological success for the Prestige ST artificial disc.<sup>6</sup> Heller et al and

Coric et al documented statistically significant greater overall composite success rates for Bryan and Kineflex|C, respectively.<sup>5, 34</sup> Davis and associates reported statistically superior overall success for 2-level surgery with Mobi-C.<sup>10</sup> Murrey and associates reported statistically significant decrease in secondary surgeries following Prodisc-C placement.<sup>7</sup> Vaccarro et al showed statistically superiority in favor of SECURE-C in terms of overall success, secondary surgery as well as patient satisfaction.<sup>8</sup> Phillips et al reported statistically significant lower NDI scores and dysphagia rates as well as higher patient satisfaction for PCM.<sup>35</sup>

The composite overall success rate reported from the IDE studies favor arthroplasty over ACDF. The following cTDR devices showed greater composite overall success (Prestige ST 79% vs 68%; Prodisc-C 72% vs 68%; Bryan 83% vs 73%; Kineflex|C 85% vs 71%; SECURE-C 84% vs 73%; PCM 75% vs 65%; Mobi-C 1-level 74% vs 65%, 2-level 70% vs 37%)(Table 2).<sup>10, 17, 34, 35, 36, 37, 38</sup>

Table 2. Composite overall success rates from pivotal IDE study, cTDR versus ACDF.

<i>IDE study</i>	<i>cTDR</i>	<i>ACDF</i>
Prestige ST	79%	68%
Prodisc-C	72%	68%
Bryan Disc	83%	73%
Secure-C	84%	73%
PCM	75%	65%
Mobi-C 1-level	74%	65%
Mobi-C 2-level	70%	37%
Kineflex/C	85%	71%

Range of motion data from the IDE studies confirm that cervical arthroplasty devices maintain segmental motion (in degrees) at the treated level: Prestige ST (7.7), Bryan (6.5), Prodisc-C (8.4), Kineflex|C (9.8), SECURE-C (9.7), PCM (5.7), Mobi-C 1-level (10.8) and 2-level (10.1, 8.3) (Table 3).<sup>10, 17, 34, 35, 36, 37, 38</sup>

Table 3. Range of motion (ROM) for cTDR devices from pivotal IDE study.

<i>IDE study</i>	<i>Mean ROM (degrees)</i>
Prestige ST	7.7
Prodisc-C	8.4
Bryan Disc	6.5
Secure-C	9.7
PCM	5.7
Mobi-C 1-level	10.8
Mobi-C 2-level	10.1, 8.3

The results of these multi-center studies have been replicated with single center results.<sup>1, 33, 39, 40</sup> Coric demonstrated statistically higher overall success rates from a single institution utilizing three different cTDR devices.<sup>33</sup> Jawahar also combined data from three separate cTDR devices and reported clinical equivalence between arthroplasty and fusion, but no change in adjacent level disease at two years.<sup>40</sup> Garrido reported long-term outcomes for the Bryan disc from a single site which favored cTDR on NDI, VAS and fewer additional surgeries.<sup>39</sup> Level 2 and 3 data from single sites outside the United States (OUS) have also shown positive clinical results. Goffin<sup>4</sup> and Kim<sup>41</sup> reported safety and efficacy with 1- and 2-level cervical arthroplasty using the Bryan disc. Bertagnoli<sup>15</sup> and Beurain<sup>42</sup> also showed good results with Prodisc-C and Mobi-C, respectively, at two year follow-up.

Intermediate and long-term follow-up studies, ranging from 4- to 10-years, have also been published.<sup>31, 43, 44, 45, 46</sup> Burkus and associates reported statistically higher rate of disability (NDI) improvement at 3- and 5-years for cTDR with Prestige ST. They also showed a statistically lower rate of index level surgery for cTDR at 5-years.<sup>43</sup> Similarly, Delamarter et al reported a statistically higher rate of VAS satisfaction at all time points out to 4-year follow-up for Prodisc-C cTDR over ACDF. They also reported a statistically lower rate of index level surgery for cTDR at four years.<sup>46</sup> Zigler et al reaffirmed those positive results out to five year follow-up.<sup>45</sup> Quan reported eight-year outcomes on the Bryan disc using Odom criteria and showed good/excellent results in 90% of patients.<sup>31</sup> Coric et al reported that in both cTDR and ACDF groups, the mean NDI and VAS scores improved significantly by 6 weeks and remained significantly improved from 4- to 8-year follow-up.<sup>44</sup>

There is considerably less literature examining the use of cervical arthroplasty for multi-level cervical spondylosis. Several studies have reported positive results for cTDR in patients with 2-level disease.<sup>4, 41, 47</sup> As previously discussed, Davis et al<sup>10</sup> reported Level 1 data from the prospective, randomized IDE study comparing 2-level cTDR with Mobi-C compared to 2-level ACDF. These authors reported dramatically improved overall success with arthroplasty (70% versus 37%) over fusion.

Several meta-analyses examining cTDR performance have also been published.<sup>37, 38, 48, 49</sup> Bartels et al published a meta-analysis of six peer-reviewed articles and three meeting abstracts. These authors reported statistically superior results for cTDR in pain (VAS) and function (SF-36) at 12 months and disability (NDI) at 24 months, yet concluded that there was no proven clinical benefit for arthroplasty.<sup>48</sup> McAfee and associates combined the results of four separate IDE studies and reported statistical superiority for overall success, neurologic success and survivorship success for cTDR.<sup>37</sup> Upadhyaya and co-authors combined the completed data sets from the first 3 FDA-approved cTDR devices and reported statistically significantly lower reoperation rate for adjacent level disease as well as superior neurological success.<sup>38</sup>

It is well understood that fusion sacrifices motion at the index level and places stresses on adjacent levels.<sup>3, 12, 13, 18, 21, 23, 25, 26, 27, 29, 50, 51, 52</sup> The consequences of those stresses are much less understood. Adjacent level disease is likely a multifactorial process involving several disparate factors including natural history of the underlying disease process

(spondylosis), surgical technique, patient selection and type of instrumentation employed. It is also well established that arthroplasty maintains motion decreases adjacent level stress compared to fusion.<sup>16, 19, 29, 30, 53, 54, 55, 56, 57</sup> But the clinical benefits of this decreased stress remain debatable.<sup>34</sup> It is important to differentiate between adjacent level degeneration (deterioration above or below the operative level evident on radiographic imaging) and adjacent level disease (clinically symptoms attributable to a level above or below the operative level). The only Level 1 studies to document statistically significant decrease in adjacent level disease for cervical arthroplasty are the previously discussed meta-analysis papers by McAfee<sup>37</sup> and Upadhyaya.<sup>38</sup> A decreased rate of adjacent deterioration from the IDE studies in favor of arthroplasty devices was reported by Coric<sup>34</sup> (9% vs 25%), Davis<sup>10</sup> (11% vs 23%) and Vaccarino.<sup>8</sup> Kim and associates also reported decreased degenerative change in patients treated with the Bryan artificial disc.<sup>40</sup>

There are several unique complications associated with cTDR devices including subsidence/dislocation, wear debris/osteolysis and heterotopic ossification.<sup>58, 59, 60, 61</sup> The published results of IDE studies generally show low rates of reoperation<sup>43, 46</sup> with the majority of these related to persistent neck pain without device failure. The rate of bridging heterotopic bone across these studies was also low, ranging from 0-3%.<sup>5, 6, 7, 8, 10, 34</sup>

## Conclusion

Anterior cervical discectomy and fusion has an established record of clinical and radiographic efficacy.<sup>12, 14, 27, 62, 63</sup> The safety and efficacy of cervical arthroplasty has been established with a growing body of Level 1 evidence that is compelling enough to no longer consider cTDR investigational.<sup>33</sup> This evidence is bolstered by experience with multiple devices, at multiple sites, in and out of the investigational setting and with short-, intermediate- and long-term follow-up. cTDR is a viable alternative to ACDF in select patients with symptomatic 1- and 2-level cervical radiculopathy or myelopathy (Table 4).

Table 4. Indications for cervical total disc replacement (cTDR).

Cervical arthroplasty is indicated in patients meeting the following criteria:

- Skeletally mature
- Clinically symptomatic cervical radiculopathy and/or myelopathy due to neural compression C3-C7 at one-level or two contiguous levels
- Failed at least 6 weeks of nonsurgical treatment or shows signs of progressively clinical deterioration

Clinically symptomatic pertains to one of the following:

- Intractable radiculopathy (arm pain and/or a neurological deficit) with or without associated neck pain
- Myelopathy (due to abnormality localized to the level of the disc space)

## References

1. Coric D, Finger F, Boltes P: The Bryan Cervical Disc prospective, randomized, controlled study: Early clinical results from a single investigational site. *J Neurosurg-Spine* 41:31-35, 2006
2. Goffin J, Casey A, Kehr P, Lebig K, Lind B, Logroscino C, et al: Preliminary clinical experience with the Bryan cervical disc prosthesis. *Neurosurg* 51:840-847, 2002
3. Goffin J, Geusens E, Vantomee N, Quintens E, Waerzeggers Y, Depreitere B, et al: Long-term follow-up after interbody fusion of the cervical spine. *J Spine Disord Tech* 17:79-85, 2004
4. Goffin J, Van Calenbergh F, van Loon J, Casey A, Kehr P, Liebig KE et al: Intermediate follow-up after treatment of degenerative disc disease with the Bryan cervical disc prosthesis: single-level and bi-level. *Spine* 23:2673-2678, 2003
5. Heller JG, Sasso RC, Papadopoulos SM, Anderson PA, Fessler RG, Hacker RJ, Coric D, Cauthen JC, Riew DK: Comparison of BRYAN Cervical Disc Arthroplasty With Anterior Cervical Decompression and Fusion. *Spine* 34:101-107, 2008
6. Mummaneni P, Burkus J, Haid R, Traynelis V, Zdeblick T: Clinical and radiographic analysis of cervical disc arthroplasty compared with allograft fusion: a randomized controlled clinical trial. *J Neurosurg-Spine* 6:198-200, 2007
7. Murrey D, Janssen M, Delamarter R, Goldstein J, Zigler J, et al: Results of the prospective, randomized controlled multicenter Food and Drug Administration investigational device exemption study of the ProDisc-C total disc replacement versus anterior discectomy and fusion for the treatment of 1-level symptomatic cervical disc disease. *Spine J* 9:275-286, 2009
8. Vaccaro A, Beutler W, Peppelman W, et al: Clinical outcomes with selectively constrained SECURE-C cervical disc arthroplasty: Two-year results from a prospective, randomized, controlled, multicenter Investigational Device Exemption study. *Spine* 38:2227-2239, 2013
9. Phillips F, Lee J, Geisler F, et al: A prospective, randomized, controlled clinical investigation comparing PCM cervical disc arthroplasty with anterior cervical discectomy and fusion. 2 year results from the US FDA IDE clinical trial. *Spine* 38:E907-918, 2013
10. Davis RJ, Kim KD, Hisey MS, et al: Cervical total disc replacement with Mobi-C®cervical artificial disc versus anterior discectomy and fusion for the treatment of two-level symptomatic degenerative disc disease: a prospective, randomized, controlled multicenter clinical trial. *J Neurosurg-Spine* 19:532-545, 2013
11. Aronson N, Filtzer D, Bagan M: Anterior cervical fusion by the Smith-Robinson approach. *J Neurosurg* 29:396-404, 1968
12. Bohlman HH, Emery SE, Goodfellow DB, Jones PK: Robinson anterior cervical discectomy and arthrodesis for cervical radiculopathy. Long-term follow-up of one hundred and twenty-two patients. *JBJS-A* 75:1298-1307, 1993
13. Gore DR, Sepic SB: Anterior cervical fusion for degenerated or protruded discs: a review of one hundred and forty-six patients. *Spine* 9:667-671, 1984

14. Smith GW, Robinson RA: The treatment of certain cervical spine disorders by anterior removal of the intervertebral disc and interbody fusion. *JBJS(A)* 40:607-624, 1958
15. Bertagnoli R, Yue J, Pfeiffer F, Fenk-Mayer A, Lawrence J, Kershaw T, et al: Early results after Prodisc-C cervical disc replacement. *J Neurosurg-Spine* 2:403-410, 2005
16. DiAngelo D, Roberston J, Metcalf N, McVay B, Davis R: Biomechanical testing of an artificial cervical joint and an anterior cervical plate. *J Spinal Disord Tech* 16(4):314-323, 2003
17. Mummaneni P, Haid R. The future in the care of the cervical spine: interbody fusion and arthroplasty. *J Neurosurg-Spine* 2:155-159, 2004
18. Baba H, Furusawa N, Imura S, Kawaharea N, Tsuchiya H, Tomita K: Late radiographic findings after anterior cervical fusion for spondylotic myeloradiculopathy. *Spine* 18:2167-2173, 1993
19. Eck JC, Humphreys SC, Lim TH, Jeong ST, Kim JG, Hodges SD, et al.: Biomechanical study on the effect of cervical spine fusion on adjacent intradiscal pressure and segmental motion. *Spine* 27:2431-2434, 2002
20. Hilibrand A, Carlson G, Palumbo M, Jones P, Bohlman H: Radiculopathy and myelopathy at segments adjacent to the site of a previous anterior cervical arthrodesis. *J Bone Joint Surg(A)* 81:519-528, 1999
21. Kulkarni V, Rajshekhar V, Raghuram L: Accelerated spondylotic changes adjacent to the fused segment following central cervical corpectomy: magnetic resonance imaging study evidence. *J Neurosurg* 100(1 Suppl):2-6, 2004
22. Matsunaga S, Kabayama S, Yamamoto T, Yone K, Sakou T, Nakanishi K: Strain on intervertebral discs after anterior cervical decompression and fusion. *Spine* 24:670-675, 1999
23. Pospisch J, Stolke D, Wilke H, Claes L: Intradiscal pressure recordings in the cervical spine. *Neurosurg* 44:379-385, 1999
24. Wang J, McDonough P, Endow K, Kanin L, Delamarter R: The effect of cervical plating on single-level anterior cervical discectomy and fusion. *J Spinal Disord* 112:467-471, 1999
25. Weinhoffer SL, Guyer RD, Herbert M, Griffith SL: Intradiscal pressure measurements above an instrumented fusion. A cadaveric study. *Spine* 20:526-531, 1995
26. Wigfield C, Skrzypiec D, Jackowski A, Adams M: Internal stress distribution in cervical intervertebral discs: the influence of an artificial cervical joint and simulated anterior interbody fusion. *J Spinal Disord Tech* 16:441-449, 2003
27. Yue WM, Brodner W, Highland TR: Long-term results after anterior cervical discectomy and fusion with allograft and plating: a 5- to 11-year radiologic and clinical follow-up study. *Spine* 30:2138-44, 2005
28. Fountas FN, Kapalaki EZ, Nikolakakos LG, Smissen HF, Johnston KW, Grigorian AA, Lee GP, Robinson JS: Anterior cervical discectomy and fusion associated complications. *Spine* 32:2310-2317, 2007
29. Chang U-K, Kim DH, Lee MC, Willenberg R, Kim S-H, Lim J: Changes in adjacent-level disc pressure and facet joint force after cervical arthroplasty compared with cervical discectomy and fusion. *J Neurosurg-Spine* 7:33-39, 2007

30. Dmitriev AE, Cunningham BW, Hu N, Sell G, Vigan F, McAfee PC: Adjacent level intradiscal pressure and segmental kinematics following a cervical total arthroplasty: an in vitro human cadaveric model. *Spine* 30:1165-1172, 2005
31. Quan G, Vital J, Hansen S, et al: Eight-year clinical and radiological follow-up of the Bryan cervical disc arthroplasty. *Spine* 36:639-646, 2011
32. Robertson JT, Papadopoulos SM, Traynelis VC: Assessment of adjacent-segment disease in patients treated with cervical fusion or arthroplasty: a prospective 2-year study. *J Neurosurg-Spine* 3:417-423, 2005
33. Coric D, Cassis J, Carew JD, Boltes MO: Prospective Study of Cervical Arthroplasty: 98 Patients from Three Separate IDE Studies from a Single Investigational Site with Minimum Two Year Follow-up. *J Neurosurg-Spine* 13:715-721, 2010
34. Coric D, Nunley P, Guyer RD, et al: Prospective, randomized, multicenter study of cervical arthroplasty: 269 patients from the Kineflex®|C artificial disc IDE study with minimum two year follow-up. *J Neurosurg-Spine* 15:348-358, 2011
35. Phillips FM, Allen TR, Regan JJ, Albert TJ, Cappuccino A, Devine JG, Ahrens JE, Hipp JA, McAfee PC: Cervical disc replacement in patients with and without previous adjacent level fusion surgery: a prospective study. *Spine* 34:556-565, 2009
36. Fraser JF, Hartl R: Anterior approaches to fusion of the cervical spine a meta-analysis of fusion rates. *J Neurosurg Spine* 6:298-303, 2007
37. McAfee PC, Reah C, Gilder K, Eisermann L, Cunningham B: A meta-analysis of comparative outcomes following cervical arthroplasty or anterior cervical discectomy and fusion: results from 4 prospective multicenter randomized clinical trial and up to 1226 patients. *Spine* 37:943-952, 2012
38. Upadhyaya CD, Wu JC, Haid RW, et al: Analysis of the three US FDA-IDE cervical arthroplasty trials. *J Neurosurg-Spine* 16:216-228, 2012
39. Garrido BJ, Taha TA, Sasso RC: Clinical outcomes of Bryan cervical disc arthroplasty a prospective, randomized, controlled, single site trial with 48-month follow-up. *J Spinal Disord Tech* 23:367-371, 2010
40. Jawahar A, Cavanaugh D, Kerr E, Birdsong E, Nunley P: Total disc arthroplasty does not affect the incidence of adjacent segment degeneration in cervical spine: results of 93 patients in three prospective randomized clinical trials. *Spine J* 10:1043-1048, 2010
41. Kim SW, Limson MA, Kim SB, Arbatin JJ, Chang KY, Park MS et al: Comparison of radiographic changes after ACDF versus Bryan disc arthroplasty in single and bi-level cases. *Eur Spine J* 18:218-231, 2009
42. Beaurain J, Bernard P, Dufour T, Fuentes J, Hovorka I, et al: Intermediate clinical and radiological results of cervical TDR (Mobi-C) with up to 2 years of follow-up. *Eur Spine J* 18:841-850, 2009
43. Burkus JK, Haid RW, Traynelis VC, and Mummaneni PV: Long-clinical and radiographic outcomes of cervical disc replacement with the Prestige disc: results from a prospective randomized controlled clinical trial. *J Neurosurg-Spine* 13:308-318, 2010
44. Coric D, Kim PK, Clemente J, Boltes MO, Nussbaum M, James S: Prospective, randomized study of cervical arthroplasty and ACDF with long-term follow-up:

- 74 patients from a single site with four- to eight-year follow-up. *J Neurosurg-Spine* 18:85-95, 2013
- 45. Zigler JE, Delamarter RB, Murrey D, Spivak J, Janssen M: ProDisc-C and ACDF as surgical treatment for single level cervical symptomatic degenerative disc disease: Five-year results of an FDA study. *Spine* 38:203-209, 2013
  - 46. Delamarter RB, Murrey D, Janssen ME, Goldstein JA, Zigler J, Tay BKB: Results at 24 months from the prospective, randomized, multicenter Investigational Device Exemption trial of Prodisc-C versus anterior cervical discectomy and fusion with 4-year follow-up and continued assess patients. *IJSS* 4:122-128, 2010
  - 47. Huppert J, Beaurain J, Steib J, Bernard P, Dufour T, et al: Comparison between single- and multi-level patients: clinical and radiological outcomes 2 years after cervical disc replacement. *Eur Spine J* 20:1417-1426, 2011
  - 48. Bartels R, Donk R, Verbeek A: No justification for cervical disk prostheses in clinical practice: a meta-analysis of randomized controlled trials. *Neurosurg* 66:1153-1160, 2010
  - 49. Gao Y, Liu M, Li T, Huang F, Tang T, Xiang Z: A meta-analysis comparing the results of cervical disc arthroplasty with anterior cervical discectomy and fusion (ACDF) for the treatment of symptomatic cervical disc disease. *J Bone & Joint Surg Am* 95:555-61, 2013
  - 50. Hunter L, Braunstein E, Bailey R: Radiographic changes following anterior cervical fusion. *Spine* 5:399-401, 1980
  - 51. Ishihara H, Kanamori M, Kawaguchi Y, Nakamura H, Kimura T: Adjacent segment disease after anterior cervical interbody fusion. *Spine J* 4:624-8, 2004
  - 52. Reitman CA, Hipp JA, Nguyen L, Esses SI: Changes in segmental intervertebral motion adjacent to cervical arthrodesis: a prospective study. *Spine* 29:E221-6, 2004
  - 53. Cunningham BW, Hu N, Zorn CM, McAfee PC: Comparative fixation methods of cervical disc arthroplasty versus conventional methods of anterior cervical arthrodesis: serration, teeth, keels, or screws? *J Neurosurg Spine* 12:214-220, 2010
  - 54. Park DK, Lin EL, Phillips FM: Index and adjacent level kinematics after cervical disc replacement and anterior fusion: in vivo quantitative radiographic analysis. *Spine* 36:721-730, 2011
  - 55. Puttlitz CM, Rousseau MA, Xu Z, Hu S, Tay BK, Lotz JC: intervertebral disc replacement maintains cervical spine kinetics. *Spine* 29:2809-14, 2004
  - 56. Rabi D, Bertagnoli R, Wharton N, Pickett GE, Duggal N: Sagittal balance influences range of motion: an in vivo study with the ProDisc-C. *Spine J* 9:128-133, 2009
  - 57. Wigfield C, Gill S, Nelson R, Langdon I, Metcalf N, Robertson JT: Influence of an artificial cervical joint compared with fusion on adjacent-level motion in the treatment of degenerative cervical disc disease. *J Neurosurg-Spine* 1:17-21, 2002
  - 58. Bartels R, Donk R: Fusion around cervical disc prosthesis: case report. *Neurosurg* 57:194, 2005
  - 59. Parkinson JF, Sekhon L: Cervical arthroplasty complicated by delayed spontaneous fusion: case report. *J Neurosurg-Spine* 2:377-380, 2005
  - 60. Pickett GE, Sekhon LHS, Sears WR, Duggal N: Complications with cervical arthroplasty. *J Neurosurg-Spine* 4:98-105, 2006

61. Sears WR, Duggal N, Sekhon LH, Williamson OD: Segmental malalignment with the Bryan cervical disc prosthesis--contributing factors. *J Spinal Disord Tech*20:111-117, 2007
62. Bailey RW, Badgley CE: Stabilization of the cervical spine by anterior fusion. *JBJS-A* 42:565-594, 1960
63. Cloward RB: The anterior approach for removal of ruptured cervical discs. *J Neurosurg* 15:602-617, 1958

## Corresponding Author

Dr. Dom Coric, Email: dom@csna.com

## Disclosures

Dr. Coric is a consultant to Pioneer Surgical, Medtronic, Globus Medical, Spine Motion, & Spine Wave. He owns private stock in Spine Motion & Spine Wave.

Copyright © 2014 ISASS - International Society for the Advancement of Spine Surgery.  
To see more or order reprints or permissions, see <http://ijssurgery.com>.